Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress

Molecular Pharmacology

Volumn 82, Issue 6, 2012, Pages 1217-1229

  Cruickshanks, Nichola ^a   Tang, Yong ^a   Booth, Laurence ^a   Hamed, Hossein ^b   Grant, Steven ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; OBATOCLAX; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL DEATH; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMAN; LETHALITY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRROLES; QUINAZOLINES; REACTIVE OXYGEN SPECIES;

EID: 84869757978     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.081539     Document Type: Article

References (41)

1. Alva AS, Gultekin SH, and Baehrecke EH (2004) Autophagy in human tumors: cell survival or death? Cell Death Differ 11:1046-1048. (Pubitemid 39232364)
2. Amaravadi R (2009) Autophagy can contribute to cell death when combining targeted therapy. Cancer Biol Ther 8:130-133.
3. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, and Gianni L (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16-32.
4. Awada A, Saliba W, and Bozovic-Spasojevic I (2011) Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. Drugs Today (Barc) 47:335-345.
5. Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, and Dent P (2012) Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol Pharmacol 81:748-758.
6. Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Gupta P, Emdad L, Lebedeva IV, et al. (2010) MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs 21:725-731.
7. Depowski PL, Rosenthal SI, and Ross JS (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14:672-676. (Pubitemid 32667211)
8. Eulitt PJ, Park MA, Hossein H, Cruikshanks N, Yang C, Dmitriev IP, Yacoub A, Curiel DT, Fisher PB, and Dent P (2011) Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol Ther 10:1290-1305.
9. Gewirtz DA (2007) Autophagy as a mechanism of radiation sensitization in breast tumor cells. Autophagy 3:249-50.
10. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743. (Pubitemid 46021510)
11. Graf MR, Jia W, Johnson RS, Dent P, Mitchell C, and Loria RM (2009) Autophagy and the functional roles of Atg5 and beclin-1 in the anti-tumor effects of 3βandrostene 17α diol neuro-steriod on malignant glioma cells. J Steroid Biochem Mol Biol 115:137-145.
12. Hippert MM, O'Toole PS, and Thorburn A (2006) Autophagy in cancer: good, bad, or both? Cancer Res 66:9349-9351.
13. Höland K, Salm F, and Arcaro A (2011) The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Curr Cancer Drug Targets 11:894-918.
14. Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354. (Pubitemid 40637826)
15. Jia W, Loria RM, Park MA, Yacoub A, Dent P, and Graf MR (2010) The neurosteroid, 5-androstene 3β,17α diol; induces endoplasmic reticulum stress and autophagy through PERK/Eif2α signaling in malignant glioma cells and transformed fibroblasts. Int J Biochem Cell Biol 42:2019-2029.
16. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, and Larijani B (2008) HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PloS One 3:e2881.
17. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, et al. (2008) Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 74:807-822.
18. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, and Dent P (2009) Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 8:2084-2096.
19. Mathew R, Karantza-Wadsworth V, and White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7:961-967. (Pubitemid 350165856)
20. Mehrpour M, Esclatine A, Beau I, and Codogno P (2010) Autophagy in health and disease. 1. Regulation and significance of autophagy: an overview. Am J Physiol Cell Physiol 298:C776-C785.
21. Miller KD (2004) The role of ErbB inhibitors in trastuzumab resistance. Oncologist 9 (Suppl 3):16-19.
22. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, and Dent P (2010) Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10:903-917.
23. Ni Chonghaile T and Letai A (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27 (Suppl 1):S149-S157.
24. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, and Dent P (2010) Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 70:6313-6324.
25. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, et al. (2008) Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 7:1648-1662.
26. Parkin DM, Bray F, Ferlay J, and Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
27. Pattingre S, Espert L, Biard-Piechaczyk M, and Codogno P (2008) Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 90:313-323. (Pubitemid 351181247)
28. Rahmani M, Davis EM, Bauer C, Dent P, and Grant S (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-35227. (Pubitemid 41532709)
29. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, and Grant S (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27:5499-5513. (Pubitemid 47124402)
30. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, Botrugno OA, Parazzoli D, Oldani A, Minucci S, et al. (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471:74-79.
31. Rodriguez-Rocha H, Garcia-Garcia A, Panayiotidis MI, and Franco R (2011) DNA damage and autophagy. Mutat Res 711:158-166.
32. Seminario MC, Precht P, Wersto RP, Gorospe M, and Wange RL (2003) PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression. Oncogene 22:8195-8204. (Pubitemid 37487310)
33. Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, and Dent P (2012) Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol 81:527-540.
34. Tao RH and Maruyama IN (2008) All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 121:3207-3217.
35. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, et al. (2012) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770-781.
36. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, and Dent P (2007) Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 6:789-801. (Pubitemid 46554549)
37. van Delft MF and Huang DC (2006) How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16:203-213.
38. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, and Heasley LE (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 5:e14117.
39. Yoon JH, Ahn SG, Lee BH, Jung SH, and Oh SH (2012) Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol 83:747-757.
40. Yoshimori T and Noda T (2008) Toward unraveling membrane biogenesis in mammalian autophagy. Curr Opin Cell Biol 20:401-407.
41. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, and Dent P (2008) Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14:5385-5399.